Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-1 in Advanced Colorectal Carcinoma
NCT00361842Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2006
- Primary completion
- Dec 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of floxuridine liposome in colorectal carcinoma (CRC), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Objective Response Rate up to 48 months and Progression-free Survival. Started Jul 2006; status: completed.
02
Drugs
floxuridine liposome
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00361842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361842.